Genmab Reports Q2 2025 DARZALEX Sales of $3.539B, Up 27% YoY

Genmab reported net sales of DARZALEX (daratumumab) for Q2 2025 at $3,539 million, with royalties received on worldwide net sales from Johnson & Johnson. Sales totaled $2,017 million in the US and $1,521 million in the rest of the world. Genmab receives royalties on net sales under an exclusive worldwide license to J&J.

Genmab A/S (NASDAQ: GMAB) reported robust net sales of DARZALEX (daratumumab) for the second quarter of 2025, totaling USD 3,539 million. This significant performance was driven by strong sales of both the intravenous and subcutaneous (SC) versions of the drug, with the SC product, DARZALEX FASPRO®, contributing to the overall growth.

The company's net sales in the United States reached USD 2,017 million, while sales in the rest of the world amounted to USD 1,521 million. Genmab receives royalties on net sales of DARZALEX under an exclusive worldwide license agreement with Johnson & Johnson (J&J), which further underscores the financial impact of these sales on Genmab's revenue.

Genmab's strong Q2 performance can be attributed to the growing demand for DARZALEX in the treatment of multiple myeloma and other indications. The company's ability to maintain a significant market share in this competitive landscape highlights its innovative approach to developing and commercializing antibody therapeutics.

Looking ahead, Genmab continues to focus on expanding its product pipeline and leveraging its proprietary antibody technology platforms to improve patient outcomes. The company's commitment to innovation and collaboration with leading pharmaceutical partners, such as J&J, positions it well for future growth.

References:
[1] https://finance.yahoo.com/news/ubs-maintains-buy-genmab-gmab-151402375.html
[2] https://www.nasdaq.com/articles/andrew-hill-dumps-38000-johnson-johnson-shares-q2-2025-exit
[3] https://www.globenewswire.com/news-release/2025/07/16/3116237/0/en/Genmab-Announces-Net-Sales-of-DARZALEX-daratumumab-for-Second-Quarter-of-2025.html